The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report evaluating the comparative clinical effectiveness and value of inclisiran (Novartis), bempedoic acid (Nexletol™, Esperion Therapeutics, Inc.), and bempedoic acid/ezetimibe (Nexlizet™, Esperion Therapeutics, Inc.) for patients with heterozygous familial hypercholesterolemia and for secondary prevention of ASCVD. This is a preliminary draft marking the midpoint of ICER’s assessments, the findings are not ICER’s final conclusions.
Public comment period on preliminary draft now open until December 11, 2020. All stakeholders are invited to submit formal comments by email to email@example.com. Guidelines for submitting public comments, including formatting specifications, are available on ICER’s website. ICER’s Manufacturer Engagement Guide and Patient Participation Guide provide additional detail on what types of information may be most informative to the report.
Download the full report here.